In mouse models, DC-Y13-27 has shown effects similar to Ythdf2 knockout, effectively enhancing the efficacy of IR and the anti-tumor effects of IR combined with PD-L1 antibody treatment [48]. The gene discussed is YTHDF2; the disease is neoplasm.